<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03208413</url>
  </required_header>
  <id_info>
    <org_study_id>2017001</org_study_id>
    <nct_id>NCT03208413</nct_id>
  </id_info>
  <brief_title>The Therapeutic Effect of Thalidomide in RI</brief_title>
  <official_title>The Effect of Thalidomide in Radiation-induced Brain Injury（RI）: a Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects&#xD;
      and side effects of thalidomide in radiation-induced brain injury.&#xD;
&#xD;
      Further study details as provided by Sun Yat-sen Memorial Hospital, Sun Yat-sen University /&#xD;
      Yameitang.&#xD;
&#xD;
      Primary outcome measure: The primary endpoint is the brain injury remission at week 15. In&#xD;
      brief, the brain lesion will be evaluated by using brain MRI scan before and after&#xD;
      thalidomide regimen. The clinical efficacy is defined as ≥ 25% reduction in brain edema&#xD;
      volume on FLAIR images at week 15, as compared with that before thalidomide usage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no acknowledged and effective standard treatment for radiation-induced brain injury&#xD;
      (RI). Glucocorticoids and bevacizumab during acute period are optional ways to reduce the&#xD;
      brain edema. However, glucocorticoids and bevacizumab are unsuitable or ineffective for some&#xD;
      patients, especially in the early stage of RI. The investigators supposed that angiogenesis&#xD;
      might play a key role in the pathogenesis of RI, and that thalidomide, as an antiangiogenic&#xD;
      drug, would reduce immature angiogenesis and improve vessel maturation in RI.&#xD;
&#xD;
      Primary objectives: This phase II clinical trial aims to evaluate the indications,&#xD;
      therapeutic effects and safety of thalidomide in radiation-induced brain injury.&#xD;
&#xD;
      OUTLINE: This is a phase II, open-label, single arm clinical trial. Patients are enrolled and&#xD;
      administrated with thalidomide. Thalidomide is supplied as 25 mg per pill to be taken by&#xD;
      mouth.&#xD;
&#xD;
      Arm І: Patients receive thalidomide with a dosage of 25 mg at bedtime daily one week (days&#xD;
      1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for&#xD;
      one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the&#xD;
      absence of unacceptable toxicity or severe deterioration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 19, 2017</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the brain injury remission</measure>
    <time_frame>Week 15</time_frame>
    <description>The brain injury remission is defined as ≥ 25% reduction in brain edema volume on FLAIR images at week 15, as compared with that before thalidomide usage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement of quality of life</measure>
    <time_frame>Week 15</time_frame>
    <description>the difference value of WHO-QOL scale before and after thalidomide regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement of neurological function</measure>
    <time_frame>Week 15</time_frame>
    <description>the difference value of LENT/SOMA scales before and after thalidomide regimen</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Radiation Injuries</condition>
  <arm_group>
    <arm_group_label>thalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.</description>
    <arm_group_label>thalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Prior irradiation &gt;/= 12 months prior to study entry.&#xD;
&#xD;
          -  Radiographic evidence to support the diagnosis of radiation-induced brain injury&#xD;
             without tumor recurrence.&#xD;
&#xD;
          -  Age&gt;/= 35 years.&#xD;
&#xD;
          -  Contraindication to glucocorticoids and bevacizumab treatment due to history or high&#xD;
             risk of severe adverse effects, or non-effective response to glucocorticoids and&#xD;
             bevacizumab treatment in 12 months prior to study entry.&#xD;
&#xD;
          -  Estimated life expectancy must be greater than 12 months.&#xD;
&#xD;
          -  Routine laboratory studies: bilirubin &lt;/=1.0 * upper limits of normal (ULN); aspartate&#xD;
             aminotransferase (AST or SGOT) or alanine aminotransferase (ALT)&lt; 1.0 * ULN;&#xD;
             creatinine &lt;1.0 * ULN; white-cell count &gt;/= 4,000 per cubic millimeter; neutrophils&#xD;
             count &gt;/=1500 per cubic millimeter platelets &gt;/= 100,000 per cubic millimeter; Hb&#xD;
             &gt;/=110 gram per millilitres; PT, APTT, INR in a normal range.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document, or&#xD;
             constant caregivers who well understand and willingness to sign a written informed&#xD;
             consent document.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Evidence of tumor metastasis, recurrence, or invasion;&#xD;
&#xD;
          -  Current usage of bevacizumab;&#xD;
&#xD;
          -  Current usage of glucocorticoids;&#xD;
&#xD;
          -  Evidence of very high intracranial pressure that suggests brain hernia and need&#xD;
             surgery;&#xD;
&#xD;
          -  History of psychiatric diseases before radiotherapy;&#xD;
&#xD;
          -  History of seizures;&#xD;
&#xD;
          -  History of arteriosclerotic cardiovascular diseases (ASCVD), e.g. stroke, myocardial&#xD;
             infaction, unstable angina, within 6 months;&#xD;
&#xD;
          -  New York Heart Association Grade II or greater congestive heart failure;&#xD;
&#xD;
          -  Serious and inadequately controlled cardiac arrhythmia;&#xD;
&#xD;
          -  Significant vascular disease, e.g. moderate or severe carotid stenosis, aortic&#xD;
             aneurysm, history of aortic dissection;&#xD;
&#xD;
          -  Severe infection;&#xD;
&#xD;
          -  History of allergy to relevant drugs;&#xD;
&#xD;
          -  Pregnancy, lactation, or fertility program in the following 12 months;&#xD;
&#xD;
          -  History or current diagnosis of peripheral nerve disease;&#xD;
&#xD;
          -  Abnormal in liver and renal function;&#xD;
&#xD;
          -  Active tuberculosis;&#xD;
&#xD;
          -  Transplanted organs;&#xD;
&#xD;
          -  Human immunodeficiency virus;&#xD;
&#xD;
          -  Participation in other experimental studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yamei Tang, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen Memorial Hospital,Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yamei Tang, M.D., Ph.D.</last_name>
    <phone>86-13556001992</phone>
    <email>yameitang@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Li, M.D., Ph.D.</last_name>
    <phone>86-15018761512</phone>
    <email>1024254327@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer canter of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingyuan Chen, M.D., Ph.D.</last_name>
      <phone>86-15692015027</phone>
      <email>406143748@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yamei Tang, M.D., Ph.D.</last_name>
      <phone>86-13556001992</phone>
      <email>yameitang@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yi Li, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Huiai Hospital</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Zheng</last_name>
      <email>920905565@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2017</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Yamei Tang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>thalidomide</keyword>
  <keyword>radiation-induced brain injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiation Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

